GSK Gets Stung By First UK Pay-For-Delay Ruling
This article was originally published in Scrip
Executive Summary
In its first pay-for-delay decision, the UK's Competition and Markets Authority (CMA) has fined GlaxoSmithKline PLC, Britain's biggest drug maker, £37.6m ($54.4m) for alleged market abuse in striking deals to delay the launch of cheap generic copies of its antidepressant Seroxat (paroxetine).